



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

164ct \$
Patent
231/003

TECH CENTER 1600/2900

RECEIVED

AUG 24 2001

In re the Application of:) Group Art Unit: 1644
Thomas Kipps et al.) Examiner: P. Gambel
Serial No.: 08/982,272)
Filed: December 1, 1997)
For: NOVEL EXPRESSION VECTORS)
CONTAINING ACCESSORY)
MOLECULE LIGAND GENES AND)
THEIR USE FOR)
IMMUNOMODULATION AND)
TREATMENT OF MALIGNANCIES)
AND AUTOIMMUNE DISEASE)

AMENDMENT TRANSMITTAL

Box Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

Applicant(s) petitions for an extension of time under 37 CFR § 1.136 [fees: 37 CFR § 1.17(a)(1)-(5)] for the total number of months checked below:

EXTENSION (months)	Fee for Small Entity	Fee for Other Than Small Entity
1 month	<input type="checkbox"/>	\$55.00
2 months	<input type="checkbox"/>	\$195.00
3 months	<input checked="" type="checkbox"/>	\$445.00
4 months	<input type="checkbox"/>	\$695.00
5 months	<input type="checkbox"/>	\$945.00

An extension for _____ months has already been secured and the fee paid therefor of _____ is deducted from the total fee due for the total months of extension now requested.

CERTIFICATE OF MAILING
(37 C.F.R. § 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

August 16, 2001
Date of Deposit

Linda Johnson
Linda Johnson

- Extension fee due with this Request \$445.00.
- If an additional extension of time is required, please consider this a petition therefor.

FEES FOR CLAIMS:

- Applicant claims small entity status pursuant to 37 CFR 1.27.


The fees for claims (37 CFR § 1.16(b)-(d)) have been calculated as shown below:

Total Claims	50	-	20	=	30	x	\$18.00	\$540.00
Independent Claims	7	-	3	=	4	x	\$80.00	\$320.00
Multiple Dependent Claims	\$270	(if applicable)				<input type="checkbox"/>		\$0.00
TOTAL OF ABOVE CALCULATIONS								
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28.						<input checked="" type="checkbox"/>		\$430.00
TOTAL FEES FOR CLAIMS SUBMITTED HEREWITH								

- A check in the amount of _____ is enclosed to cover the above fee(s).
- Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of **\$430.00**.
- The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. **12-2475** for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayments to said Deposit Account **12-2475**.

Dated: August 16, 2001

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(858) 552-8400

Respectfully submitted,

By: _____
G. Peter Albert, Jr.
Reg. No. 37,268

#23c 9/11/01
Patent
231/003US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of:
Thomas Kipps, et al.) Group Art Unit: 1644
Serial No.: 08/982,272) Examiner: P. Gambel
Filed: December 1, 1997)
For: NOVEL EXPRESSION VECTORS)
CONTAINING ACCESSORY)
MOLECULE LIGAND GENES AND)
THEIR USE FOR)
IMMUNOMODULATION AND)
TREATMENT OF MALIGNANCIES)
AND AUTOIMMUNE DISEASE)

TECH CENTER 1600/2900

AUG 24 2001

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 16, 2001, Applicants amend as follows and make the following remarks:

AMENDMENT

In the claims:

Please cancel pending claims 1-10, 67 and 83 - 86, and add the following claims:

87. (New) A method for expressing a CD40 ligand in a human cell that expresses a CD40 ligand receptor, comprising introducing a nucleic acid sequence encoding a non-human CD40 ligand into the cell.

08/23/2001 16002901 0006077 122475 08902272
01 FC:217 465.00 CH
02 FC:202 160.00 CH
03 FC:203 270.00 CH

SEARCHED INDEXED
SERIALIZED FILED
FEB 20 2002
U.S. PATENT AND TRADEMARK OFFICE
SD-164144.3